Aslan Energy Capital signs Heads of Agreement with the Government of Karimun Regency to develop "MU CITY", a next-generation ecosystem for Clean Energy, E-mobility, Advanced Manufacturing, and Digital Innovation, powered by a 2 GW renewable-energy base.

Aslan Energy Capital signs Heads of Agreement with the Government of Karimun Regency to develop "MU CITY", a next-generation ecosystem for Clean Energy, E-mobility, Advanced Manufacturing, and Digital Innovation, powered by a 2 GW renewable-energy base.

KARIMUN, Riau Islands, Indonesia, Nov. 24, 2025 /PRNewswire/ -- Aslan Energy Capital (Aslan), headquartered in Singapore, today announced the signing of a Heads of Agreement with the Government of Karimun Regency, Riau Islands, Indonesia —...

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...

SURFIRAN CO LTD Partners with Fermentation Master Insuk Jung for New Premium Product Development

SURFIRAN CO LTD Partners with Fermentation Master Insuk Jung for New Premium Product Development

SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- SURFIRAN CO LTD has announced a strategic collaboration with Master Artisan Insuk Jung, a leading figure in Korean traditional fermentation, to co-develop innovative saffron-based premium products....

GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and...

USI Collaborates with Customer to introduce Intel® Evo™ Certified Thunderbolt™ 5 Smart Dock

USI Collaborates with Customer to introduce Intel® Evo™ Certified Thunderbolt™ 5 Smart Dock

- Pioneering high-speed connectivity and intelligent management for next-generation workspaces - SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Universal Scientific Industrial (Shanghai) Co., Ltd. (USI) today announced the successful collaboration with a...

Xinhua Silk Road: Revitalizing World Heritage fuels tourism market in SE. China's historical city of Quanzhou

Xinhua Silk Road: Revitalizing World Heritage fuels tourism market in SE. China's historical city of Quanzhou

BEIJING, Nov. 21, 2025 /PRNewswire/ -- Lazare Eloundou Assomo, director of UNESCO World Heritage Center, recently led a delegation to visit Quanzhou, a historical port city in southeast China's Fujian Province, making the city, recognized as the...

Greening Learning Spaces in Crisis Settings

Greening Learning Spaces in Crisis Settings

Education Cannot Wait and Save the Children announce partnership, in consortium with Arup and World Wildlife Fund, to set new standards for environmentally responsible temporary learning spaces. NEW YORK, Nov. 19, 2025 /PRNewswire/ -- As climate...

HyperStrong and LEAG Clean Power Sign an EPC contract to Develop 1.6 GWh Battery Energy Storage Project in Germany, Advancing Europe's Energy Transition

HyperStrong and LEAG Clean Power Sign an EPC contract to Develop 1.6 GWh Battery Energy Storage Project in Germany, Advancing Europe's Energy Transition

COTTBUS and FRANKFURT, Germany, Nov. 19, 2025 /PRNewswire/ -- HyperStrong International (Germany) GmbH (HyperStrong), a subsidiary of Beijing HyperStrong Technology Co., LTD. (688411.SH), and LEAG Clean Power GmbH, have signed an EPC (engineering,...

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells(Treg)-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in...

Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech

Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech

BEIJING, Nov. 10, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 19
  • menu
    menu